Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 5, 2021
Athenex (NASDAQ: ATNX) announced a corporate and financial update for the third quarter of 2021, scheduled for November 5, 2021, before market opening. The management will host a conference call at 8:00 AM ET. Interested participants can join by dialing in or accessing the live audio webcast. Athenex focuses on developing and commercializing cancer therapies through its Oncology Innovation Platform, Commercial Platform, and Global Supply Chain Platform. The company aims to enhance cancer treatment options and patient outcomes.
- Scheduled corporate financial update for Q3 2021 to provide key insights.
- Management's proactive communication with a conference call indicates transparency.
- No specific financial results or updates provided, leaving investors with uncertainty.
BUFFALO, N.Y., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the third quarter 2021, on Friday, November 5, 2021, before the market opens. Athenex’s management team will host a conference call and live audio webcast at 8:00am Eastern Time.
To participate in the call, dial either the domestic or international number fifteen minutes before the conference call begins:
Domestic: (877) 407-0784
International: (201) 689-8560
Passcode: 13724304
The live conference call and replay can also be accessed via audio webcast here and on the Investor Relations section of the Company’s website under “Events and Presentations,” located at http://ir.athenex.com/.
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform, and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) Cell therapy, and (4) Arginine deprivation therapy. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. For more information, please visit www.athenex.com.
Athenex Contacts
Investors
Daniel Lang, MD
Athenex, Inc.
Email: danlang@athenex.com
Caileigh Dougherty
Athenex, Inc.
Email: cdougherty@athenex.com
FAQ
When is Athenex's Q3 2021 corporate update?
What is the time for Athenex's conference call?
How can I access Athenex's conference call?
What does Athenex focus on in its business?
